دورية أكاديمية
أعرض في EDS

Impact of clinical and histopathological characteristics on the disease-free survival of stage I-II acral melanoma patients.

التفاصيل البيبلوغرافية
العنوان: Impact of clinical and histopathological characteristics on the disease-free survival of stage I-II acral melanoma patients.
المؤلفون: Borges de Barros Primo R; Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil., Brito Nobre A; Pathology Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Santos BN; Tissue Microenvironment Laboratory, Department of General Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil., Nunes LF; Connective Bone Tissue Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Fernandes R; Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil., Abrão Possik P; Program of Immunology and Tumor Biology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Santos Bernardes S; Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.; Tissue Microenvironment Laboratory, Department of General Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
المصدر: International journal of dermatology [Int J Dermatol] 2023 Oct; Vol. 62 (10), pp. 1281-1288. Date of Electronic Publication: 2023 Aug 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Blackwell Science
Original Publication: Philadelphia, Lippincott.
مواضيع طبية MeSH: Melanoma* , Skin Neoplasms*, Humans ; Disease-Free Survival ; Progression-Free Survival ; Melanoma, Cutaneous Malignant
مستخلص: Background: Acral melanoma is rare and associated with a worse prognosis compared to cutaneous melanoma in other locations. Despite this, few studies have focused on the prognosis of acral melanoma, particularly in patients with initial clinical stage. The aim of this study was to assess the impact of clinical and histopathological characteristics on the disease-free survival (DFS) of stage I-II patients.
Methods: We analyzed 154 stage I-II acral melanoma cases, all of whom underwent a review of the histopathological and clinical parameters. Patients were divided into groups based on the presence or absence of disease recurrence within 5 years. We used Cox proportional regression to analyze independent risk factors and computed DFS curves using the Kaplan-Meier method.
Results: Within 5 years, 27.9% of patients experienced disease recurrence, with 90.4% occurring during the first 3 years. Univariate and multivariate analyses did not identify any clinical parameters with a significant influence on DFS. The DFS rate at 5 years was 72.7%. The median duration of disease recurrence after the initial diagnosis was 21 months. However, Breslow thickness, presence of ulceration, >3 mitosis/mm 2 , presence of tumor-infiltrating lymphocytes (TIL), and perineural invasion were significantly associated with a decrease in time to first recurrence.
Conclusions: Despite the favorable prognosis of stage I-II acral melanoma compared with advance stage, clinical and histopathological characteristics can impact prognosis. In addition to Breslow thickness and ulceration, attention should be paid to mitotic rate, presence of TIL, and perineural invasion to optimize follow-up of acral melanoma patients diagnosed in the initial clinical stage.
(© 2023 the International Society of Dermatology.)
References: Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS. Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clinical and experimental metastasis. Volume 35. Netherlands: Springer; 2018. p. 487-493.
el Sharouni MA, van Diest PJ, Witkamp AJ, Sigurdsson V, van Gils CH. Subtyping cutaneous melanoma matters. JNCI Cancer Spectr. 2020;4(6):pkaa097.
Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, Vázquez-Cruz ME, Garcia-Salinas OI, Álvarez-Cano A, et al. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Melanoma Res. 2021;34(1):59-71.
di Carlo V, Stiller CA, Eisemann N, Bordoni A, Matz M, Curado MP, et al. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1578482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3)*. Br J Dermatol. 2022;187(3):364-380.
Lino-Silva LS, Domínguez-Rodríguez JA, Aguilar-Romero JM, Martínez-Said H, Salcedo-Hernández RA, García-Pérez L, et al. Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype. Ann Surg Oncol. 2016;23(13):4189-4194.
Chang JWC. Acral melanoma. JAMA Dermatol. 2013;149(11):1272-1273.
Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, et al. More than just acral melanoma: the controversies of defining the disease. J Pathol Clin Res. 2021;7:531-541.
Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4):427-434.
Criscito MC, Stein JA. Improving the diagnosis and treatment of acral melanocytic lesions. Melanoma Manag. 2017;4(2):113-123.
Mejbel HA, Torres-Cabala CA, Milton DR, Ivan D, Feldmeyer L, Namikawa K, et al. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol. 2021;34(3):572-583.
Sondermann W, Zimmer L, Schadendorf D, Roesch A, Klode J, Dissemond J. Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis. Medicine. 2016;95(29):e4332.
Metzgerr S, Ellwanger U, Stroebel W, Schiebel U, Rassner G, Fierlbeck G. Extent and consequences of physician delay in the diagnosis of acral melanoma. Melanoma Res. 1998;8:181-186.
Soon SL, Solomon AR, Papadopoulos D, Murray DR, McAlpine B, Washington CV. Acral lentiginous melanoma mimicking benign disease: the Emory experience. J Am Acad Dermatol. 2003;48(2 Suppl):183-188.
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 2020;144(4):500-522.
Merkel EA, Gerami P. Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab Invest. 2017;97(6):630-635.
Elefanti L, Zamuner C, Del Fiore P, Stagni C, Pellegrini S, Dall'olmo L, et al. The molecular landscape of primary acral melanoma: a multicenter study of the Italian melanoma intergroup (IMI). Int J Mol Sci. 2021;22(8):3826.
Vazquez VDL, Silva TB, Vieira MDA, de Oliveira ATT, Lisboa MV, de Andrade DAP, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8(1):4.
Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013;20(11):3618-3625.
Kolla AM, Vitiello GA, Friedman EB, Sun J, Potdar A, Daou H, et al. Acral lentiginous melanoma: a United States multi-center substage survival analysis. Cancer Control. 2021;28:107327482110535.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. http://doi.wiley.com/10.3322/caac.21409.
Nunes LF, Quintella Mendes GL, Koifman RJ. Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA). Melanoma Res. 2018;28(5):458-464.
Wang L, Wu J, Dai Z, Ji S, Jiang R. Clinical characteristics and prognosis of acral lentiginous melanoma: a single-center series of 211 cases in China. Int J Dermatol. 2021;60(12):1504-1509.
Sheen YS, Liao YH, Lin MH, Chen JS, Liau JY, Tseng YJ, et al. A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. Sci Rep. 2017;7(1):5564.
Ryu GW, Choi YD, Jin S, Chung IJ, Shin MH, Yun SJ. Volar location and degree of pigmentation are associated with poor survival and first metastasis pattern in acral melanoma. Pigment Cell Melanoma Res. 2021;34(6):1094-1104.
Von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, Van Der Pols JC, Beesley VL, et al. Risk of melanoma recurrence after diagnosis of a high-risk primary tumor. JAMA Dermatol. 2019;155(6):688-693.
Rex J, Paradelo C, Mangas C, Hilari JM, FernÁndez-Figueras MT, FerrÁndiz C. Management of primary cutaneous melanoma of the hands and feet: a clinicoprognostic study. Dermatol Surg. 2009;35(10):1505-1513.
Castaneda CA, Torres-Cabala C, Castillo M, Villegas V, Casavilca S, Cano L, et al. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol. 2017;19(12):1478-1488.
Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939-946.
Susok L, Gambichler T. Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma. J Cancer Res Clin Oncol. 2022;148(2):497-502.
Carrera C, Podlipnik S. Does acral melanoma need a distinctive prognostic staging system? Br J Dermatol. 2022;186:923-924.
Calomarde-Rees L, García-Calatayud R, Requena Caballero C, Manrique-Silva E, Traves V, García-Casado Z, et al. Risk factors for lymphatic and hematogenous dissemination in patients with stages I to II cutaneous melanoma. JAMA Dermatol. 2019;155(6):679-687.
Lyth J, Falk M, Maroti M, Eriksson H, Ingvar C. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register. J Eur Acad Dermatol Venereol. 2017;31(9):1468-1474.
Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155(3):561-569.
Lv J, Dai B, Kong Y, Shen X, Kong J. Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6(1):31432.
Lee TL, Lin MH, Liao YH, Liau JY, Sheen YS. Clinicopathological characteristics and prognosis in significantly thick acral lentiginous melanoma in Taiwan. J Formos Med Assoc. 2022;121(11):2338-2344.
Wei X, Wu D, Chen Y, Li H, Zhang R, Yao H, et al. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study*. Br J Dermatol. 2022;186(6):977-987.
Wei X, Chen Y, Yao H, Wu D, Li H, Zhang R, et al. Prognostic impact of Breslow thickness in acral melanoma: a retrospective analysis. J Am Acad Dermatol. 2022;87(6):1287-1294.
Borkowska AM, Szumera-Ciećkiewicz A, Chraszczewska M, Sokół K, Goryń T, Rutkowski PŁ. Clinical significance of tumor microenvironment in acral melanoma: a large single-institution study of Caucasians. J Clin Med. 2021;10(7):1452.
Lee WJ, Lee YJ, Shin HJ, Won CH, Chang SE, Choi JH, et al. Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes. Melanoma Res. 2018;28(5):423-434.
Scanlon P, Tian J, Zhong J, Silva I, Shapiro R, Pavlick A, et al. Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value? Hum Pathol. 2014;45(8):1656-1663.
Nagore E, Pereda C, Botella-Estrada R, Requena C, Guillén C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20(1):115-119.
Straker RJ, Krupp K, Sharon CE, Thaler AS, Kelly NJ, Chu EY, et al. Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort. Ann Surg Oncol. 2022;29(8):5207-5216.
Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B, et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Onco Targets Ther. 2019;8(7):e1593806.
Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, et al. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Mod Pathol. 2017;30(11):1538-1550.
Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, et al. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021;170(5):1487-1494.
Gualano MR, Osella-Abate S, Scaioli G, Marra E, Bert F, Faure E, et al. Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis. Br J Dermatol. 2018;178:357-362.
Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G, et al. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. Br J Dermatol. 2013;169(6):1240-1245.
Ribero S, Moscarella E, Ferrara G, Piana S, Argenziano G, Longo C. Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J Eur Acad Dermatol Venereol. 2016;30:2030-2037.
تواريخ الأحداث: Date Created: 20230819 Date Completed: 20230920 Latest Revision: 20231213
رمز التحديث: 20231215
DOI: 10.1111/ijd.16800
PMID: 37596798
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-4632
DOI:10.1111/ijd.16800